| Baseline | Week 8 | Absolute change (95% CI) | Relative change % | p-value | |
| Pulmonary function | |||||
| FEV1 L | 0.91±0.24 | 1.03±0.33 | 0.12 (−0.11–0.25) | 13.2 | 0.07 |
| FEV1 % predicted | 32.99±6.39 | 38.02±12.41 | 5.03 (−0.14–10.20) | 15.3 | 0.06 |
| RV L | 5.71±0.97 | 5.38±1.63 | −0.34 (−0.99–0.32) | −6.0 | 0.30 |
| RV % predicted | 256.03±48.31 | 236.99±66.35 | −19.04 (−49.81–11.73) | −7.4 | 0.21 |
| RV/TLC ratio | 74.83±6.32 | 70.87±10.11 | −3.96 (−8.26–0.35) | −5.3 | 0.07 |
| RV/TLC ratio % predicted | 188.77±23.97 | 177.42±25.79 | −11.35 (−22.45– −0.25) | −6.0 | 0.04 |
| SPECT-guided volumetry mL | |||||
| Target lobe | 1207.6±390.3 | 762.9±318.3 | −444.6 (−703.1– −186.1) | −36.8 | 0.004 |
| Ipsilateral, nontargeted lung | 1229.9±279.6 | 1376.0±302.8 | 146.1 (4.6–287.5) | 11.9 | 0.04 |
| Total targeted lung | 2437.6±451.9 | 2250.1±570.6 | −187.4 (−375.1–0.2) | −7.7 | 0.05 |
| Contralateral, concordant lobe | 1120.7±251.9 | 1202.9±264.7 | 82.2 (−19.6–184.0) | 7.3 | 0.10 |
| Contralateral, nonconcordant lung | 1437.9±451.5 | 1602.9±611.1 | 165.0 (−68.2–398.3) | 11.5 | 0.14 |
| Total nontargeted lung | 2558.6±578.1 | 2694.8±586.3 | 136.1 (−91.6–363.9) | 5.3 | 0.21 |
| Scintigraphy-guided ventilation % | |||||
| Target lobe | 8.38±3.98 | 5.25±3.31 | −3.13 (−5.25– −1.00) | −37.4 | 0.007 |
| Ipsilateral, nontargeted lung | 37.83±7.52 | 40.26±8.44 | 2.43 (0.06–4.80) | 6.4 | 0.04 |
| Total targeted lung | 46.31±7.18 | 45.60±7.72 | −0.72 (−3.51–2.08) | −1.6 | 0.59 |
| Contralateral, concordant lobe | 14.00±5.22 | 13.32±5.69 | −0.69 (−3.44–2.07) | −4.9 | 0.60 |
| Contralateral, nonconcordant lung | 39.69±4.22 | 41.24±6.97 | 1.56 (−1.68–4.79) | 3.9 | 0.32 |
| Total nontargeted lung | 53.69±7.18 | 54.53±7.68 | 0.84 (−1.95–3.64) | 1.6 | 0.53 |
| Scintigraphy-guided perfusion % | |||||
| Target lobe | 8.82±3.48 | 5.16±2.72 | −3.66 (−5.06– −2.26) | −41.5 | <0.001 |
| Ipsilateral, nontargeted lung | 35.67±7.51 | 36.47±8.20 | 0.80 (−1.30–2.89) | 2.2 | 0.44 |
| Total targeted lung | 44.48±8.16 | 42.56±9.24 | −1.92 (−4.85–1.00) | −4.3 | 0.19 |
| Contralateral, concordant lobe | 14.72±5.75 | 15.19±5.94 | 0.47 (−1.34–2.29) | 3.2 | 0.59 |
| Contralateral, nonconcordant lung | 40.81±7.19 | 43.08±8.32 | 2.27 (0.45–4.09) | 5.6 | 0.02 |
| Total nontargeted lung | 55.50±8.16 | 58.35±8.39 | 2.85 (0.44–5.26) | 5.1 | 0.02 |
| Patient outcomes | |||||
| 6MWT m | 298.6±120.4 | 365.9±119.9 | 67.4 (17.1–117.6) | 22.6 | 0.01 |
| NT-proBNP pg·mL−1 | 175.6±126.4 | 153.6±139.4 | −22.0 (−162.9–118.9) | −12.5 | 0.72 |
| CAT points | 24.8±7.3 | 22.6±6.2 | −2.2 (−5.7–1.4) | −8.9 | 0.21 |
Data are presented as mean±sd, unless otherwise stated. FEV1: forced expiratory volume in 1 s; RV: residual volume; TLC: total lung capacity; SPECT: single-photon emission computed tomography; 6MWT: 6-min walk test; NT-proBNP: N-terminal pro-brain natriuretic peptide; CAT: Chronic obstructive pulmonary disease Assessment Test. #: n=24.